Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study von Scinto, A F, Ferraresi, V, Milella, M, Tucci, E, Santomaggio, C, Pasquali-Lasagni, R, Vecchio, M R Del, Campioni, N, Nardi, M, Cognetti, F

Volltext

Phase II randomised trial: Gemcitabine (GEM) + Vinorelbine (VNB) vs Gemcitabine + Vindesine (VDS) in Stage IIIB/IV -NSCLC- Elderly patients (pts). Italian Association of Hospital P... von Santomaggio, C, Portalone, L, De Marinis, F, Coppolino, S

Volltext

Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer : A multicenter phase II study von SANTOMAGGIO, C, TUCCI, E, RINALDINI, M, ALGERI, R, RIGHI, R, PEPI, F, GHEZZI, P, ANDREI, A, BELLEZZA, A

Volltext

53 P - Ifosfamide, cisplatin and etoposide (ICE) combination in locally advanced non small cell lung cancer (NSCLC): a phase II study von Scinto, A.F., Milella, M., Rendina, E.A., Tonachella, R., Nardi, M., Tucci, E., Santomaggio, C., Ferraresi, V., Pasquali Lasagni, R., Del Vecchio, M.R., Cognetti, F.

Volltext

Phase II study of carboplatin + etoposide + epirubicin (CEE) in small cell lung cancer von Santomaggio, C., Di Vincenzo, M., Labardi, C., Lopes Pegna, A., Nutini, S., Righi, R., Romagnoli, E.

Volltext

Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study von MORELLI, M. F, SANTOMAGGIO, A, GUGLIELMI, F, MARTELLA, F, LANFIUTI BALDI, P, PORZIO, G, RUSSO, A, GEBBIA, N, IACOBELLI, S, MARCHETTI, P, FICORELLA, C, RICEVUTO, E, CANNITA, K, DE GALITIIS, F, TUDINI, M, BRUERA, G, MANCINI, M, PELLICCIONE, M, CALISTA, F

Volltext

Effectiveness of FIr-B/FOx and liver metastasectomies in liver-only metastatic colorectal cancer (MCRC) von Bruera, G., Cannita, K., Lanfiuti Baldi, P., Santomaggio, A., Marchetti, P., Nuzzo, G., Antonucci, A., Ficorella, C., Ricevuto, E.

Volltext

Clinical properness of poker schedule weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-B/FOx) in young-elderly metastatic colorectal cancer (MCRC) von Bruera, G., Santomaggio, A., Cannita, K., Lanfiuti Baldi, P., Tudini, M., De Galitiis, F., Marchetti, P., Antonucci, A., Ficorella, C., Ricevuto, E.

Volltext

“Poker” schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study von Santomaggio, A., Ricevuto, E., Cannita, K., Bruera, G., Tudini, M., Lanfiuti Baldi, P., Mancini, M., Porzio, G., Marchetti, P., Ficorella, C.

Volltext

The safety of dose-dense liposomal-encapsulated doxorubicin in association with docetaxel (MyTax) in breast cancer von Mancini, M, Cannita, K, Santomaggio, A, Tudini, M, De Galitiis, F, Morelli, M, Rispoli, A, Martella, F, Porzio, G, Pelliccione, M, Cocciolone, V, Lanfiuti Baldi, P, Penco, M, Romano, S, Fratini, S, Stifani, G, Marchetti, P, Ficorella, C, Ricevuto, E

Volltext